JP4672866B2 - 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体 - Google Patents

非内因性の構成的に活性化されたヒトｇタンパク質共役受容体 Download PDF

Info

Publication number
JP4672866B2
JP4672866B2 JP2000576019A JP2000576019A JP4672866B2 JP 4672866 B2 JP4672866 B2 JP 4672866B2 JP 2000576019 A JP2000576019 A JP 2000576019A JP 2000576019 A JP2000576019 A JP 2000576019A JP 4672866 B2 JP4672866 B2 JP 4672866B2
Authority
JP
Japan
Prior art keywords
endogenous
human
amino acid
receptor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000576019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003531565A (ja
JP2003531565A5 (enExample
Inventor
ベハン，ドミニク・ピー
シヤルマース，デレク・テイ
リオウ，チエン・ダブリユー
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2003531565A publication Critical patent/JP2003531565A/ja
Publication of JP2003531565A5 publication Critical patent/JP2003531565A5/ja
Application granted granted Critical
Publication of JP4672866B2 publication Critical patent/JP4672866B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000576019A 1998-10-13 1999-10-12 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体 Expired - Fee Related JP4672866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/170,496 1998-10-13
US09/170,496 US6555339B1 (en) 1997-04-14 1998-10-13 Non-endogenous, constitutively activated human protein-coupled receptors
PCT/US1999/023938 WO2000022129A1 (en) 1998-10-13 1999-10-12 Non-endogenous, constitutively activated human g protein-coupled receptors

Publications (3)

Publication Number Publication Date
JP2003531565A JP2003531565A (ja) 2003-10-28
JP2003531565A5 JP2003531565A5 (enExample) 2006-09-07
JP4672866B2 true JP4672866B2 (ja) 2011-04-20

Family

ID=22620080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000576019A Expired - Fee Related JP4672866B2 (ja) 1998-10-13 1999-10-12 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体
JP2000575892A Expired - Fee Related JP4685241B2 (ja) 1998-10-13 1999-10-12 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2000575892A Expired - Fee Related JP4685241B2 (ja) 1998-10-13 1999-10-12 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法

Country Status (14)

Country Link
US (2) US6555339B1 (enExample)
EP (1) EP1121431B9 (enExample)
JP (2) JP4672866B2 (enExample)
KR (1) KR100598752B1 (enExample)
CN (1) CN1329511C (enExample)
AT (1) ATE318311T1 (enExample)
AU (5) AU769987B2 (enExample)
CA (1) CA2342314A1 (enExample)
DE (3) DE1121431T1 (enExample)
DK (1) DK1121431T5 (enExample)
ES (1) ES2163384T3 (enExample)
IL (2) IL141965A0 (enExample)
NZ (1) NZ510331A (enExample)
WO (2) WO2000021987A2 (enExample)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
PT1133559E (pt) * 1998-11-20 2005-10-31 Arena Pharm Inc Receptor acoplato a proteina g orfao humano, rup3
GB9903767D0 (en) * 1999-02-18 1999-04-14 Univ Glasgow Receptor assay
AU6385200A (en) * 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders
JP4768946B2 (ja) * 1999-11-17 2011-09-07 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒトｇタンパク質共役型受容体の内因性および非内因性型
EP1240199A2 (en) * 1999-12-10 2002-09-18 AstraZeneca AB Method for screening of appetite control agents
JP2003517008A (ja) * 1999-12-17 2003-05-20 アストラゼネカ アクチボラグ 新規化合物
AU2001232132A1 (en) * 2000-02-18 2001-08-27 Glaxo Group Limited Novel assay
GB0003902D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
GB0003898D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
WO2001064872A2 (en) * 2000-02-29 2001-09-07 Millennium Pharmaceuticals, Inc. Gene 2465: methods and compositions for the diagnosis and treatment of cardiovascular, hepatic and bone disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1278850B1 (en) * 2000-04-26 2007-06-13 Sanofi-Aventis Deutschland GmbH Edg8 receptor, its preparation and use
EP1149907A1 (en) * 2000-04-26 2001-10-31 Aventis Pharma Deutschland GmbH EDG8 receptor, its preparation and use
AU2001250536A1 (en) * 2000-05-03 2001-11-12 Astrazeneca Ab Methods
AU2001274522A1 (en) * 2000-06-15 2001-12-24 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
EP1297130A2 (en) * 2000-06-16 2003-04-02 Incyte Genomics, Inc. G-protein coupled receptors
WO2001098494A1 (fr) * 2000-06-21 2001-12-27 Takeda Chemical Industries, Ltd Ligand de gpr8 et son adn
US20040086940A1 (en) * 2000-07-04 2004-05-06 Sachio Shibata Novel g protein-coupled receptor protein and dna thereof
WO2002013845A2 (en) * 2000-08-18 2002-02-21 Novartis Ag Inflammation related g-protein coupled receptor
AU2001286945A1 (en) * 2000-08-30 2002-03-13 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
AU2000276780A1 (en) * 2000-10-02 2001-04-23 Biofocus Discovery Limited Cellular receptor mutations predicted by multiple-sequence-allignment
EP1344823A4 (en) * 2000-11-30 2005-03-16 Takeda Chemical Industries Ltd NEW G-PROTEIN-COUPLED RECEPTOR PROTEINS AND THEIR DNAS
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
CN1516706A (zh) * 2001-02-26 2004-07-28 阿伦纳药品公司 人g蛋白偶联受体的内源性和非内源性形式
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6919176B2 (en) * 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
EP1394543B1 (en) * 2001-05-15 2007-08-29 Takeda Pharmaceutical Company Limited Screening method
US20020177190A1 (en) * 2001-05-24 2002-11-28 Yanbin Liang Recombinant simian GPR3 receptor
CA2449553A1 (en) * 2001-06-05 2002-12-19 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated versions of plant g protein-coupled receptor: gcr1
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
US20050142548A1 (en) * 2001-07-13 2005-06-30 Thomson Anne M. Allelic variants of grp50
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
US20030119742A1 (en) * 2001-11-05 2003-06-26 Millennium Pharmaceuticals, Inc. Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
EP1463759B8 (en) 2002-01-07 2013-07-10 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
EP1336655A1 (en) * 2002-01-12 2003-08-20 Aventis Pharma Deutschland GmbH Method of identifying protein CAMS (constitutively active mutants)
US20030175889A1 (en) * 2002-01-23 2003-09-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated versions of human G protein coupled receptor: FSHR
JP2005534282A (ja) * 2002-02-06 2005-11-17 バイエル・ヘルスケア・アクチェンゲゼルシャフト ニューロメジンｕ受容体に関連する疾患のための診断用および治療用物質
US7214495B2 (en) 2002-02-14 2007-05-08 Takeda Pharmaceutical Company Limited Screening method
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
AU2003241037A1 (en) * 2002-06-08 2003-12-22 Astrazeneca Ab Methods for the detection of polymorphisms in human gpr50
CN100473662C (zh) * 2002-08-01 2009-04-01 阿瑞那制药公司 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物
WO2004015426A1 (en) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
AU2003250165A1 (en) * 2002-08-06 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
WO2004017994A1 (ja) * 2002-08-22 2004-03-04 Kyowa Hakko Kogyo Co., Ltd. 喘息の予防および／または治療剤
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
PL376659A1 (pl) 2002-11-06 2006-01-09 Tularik Inc. Skondensowane związki heterocykliczne
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
WO2004050853A2 (en) * 2002-12-04 2004-06-17 Synaptic Pharmaceutical Corporation Uses of the snorf55 receptor
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
WO2004083388A2 (en) * 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2004083394A2 (en) * 2003-03-18 2004-09-30 Arena Pharmaceuticals Inc. Human g protein-coupled receptors and modulators thereof for the treatment of inflammatory disorders
JPWO2004093912A1 (ja) * 2003-04-23 2006-07-13 協和醗酵工業株式会社 好中球性炎症疾患の予防および／または治療剤
WO2004099419A2 (en) * 2003-04-30 2004-11-18 Arena Pharmaceuticals, Inc. Methods and compositions for identifying modulators of g protein-coupled receptors
EP1625159B1 (en) * 2003-05-20 2011-03-02 The University Court Of The University Of Glasgow Materials and methods relating to g-protein coupled receptor oligomers
EP1666880B1 (en) * 2003-09-11 2008-08-20 Takeda Pharmaceutical Company Limited Screening method
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
AU2004280638A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists
WO2005040829A2 (en) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005040211A2 (en) * 2003-10-23 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005040828A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005040825A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
DK1713501T3 (da) * 2004-01-29 2008-05-26 Cellzome Ag Behandling af neurodegenerative sygdomme ved anvendelse af GPR49
EP1718293A1 (en) 2004-02-20 2006-11-08 Aventis Pharmaceuticals Inc. Oxydecahydronaphthalene modulators of hm74
WO2005101005A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 32 (gpr32)
ATE486962T1 (de) * 2004-04-27 2010-11-15 Takeda Pharmaceutical Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0508988D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
US8429755B2 (en) 2005-05-26 2013-04-23 Sandisk Technologies Inc. System and method for receiving digital content
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US20090313708A1 (en) * 2005-10-14 2009-12-17 Liaw Chen W Gpr22 and methods relating thereto
WO2007058930A1 (en) 2005-11-10 2007-05-24 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of obesity and conditions related thereto
CN101688203B (zh) 2007-03-22 2013-12-11 赫普泰雅治疗有限公司 突变的g蛋白偶联受体及其选择方法
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2010091692A2 (en) * 2009-04-30 2010-08-19 H. Lundbeck A/S Constitutively active mutants and uses thereof
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
US20110256157A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
JP2013534520A (ja) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
JP5804341B2 (ja) * 2010-08-06 2015-11-04 国立大学法人山口大学 エストロゲン関連疾患の判定方法
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
HRP20151374T1 (hr) 2011-10-14 2016-01-15 Medimmune Limited Pirolobenzodiazepini i njihovi konjugati
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP6392764B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
JP6270859B2 (ja) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ ピロロベンゾジアゼピン−抗体結合体
LT2906251T (lt) 2012-10-12 2017-12-11 Adc Therapeutics Sa Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
HRP20182129T1 (hr) 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105307685B (zh) 2013-03-13 2019-03-08 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TW201518323A (zh) 2013-07-25 2015-05-16 Novartis Ag 合成ａｐｅｌｉｎ多肽之生物結合物
SG11201600211XA (en) 2013-07-25 2016-02-26 Novartis Ag Cyclic polypeptides for the treatment of heart failure
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
AU2014364927A1 (en) 2013-12-16 2016-07-07 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082874A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
CA2945706C (en) * 2014-04-25 2023-10-24 Libramen Naturals Inc. G-protein coupled receptor 22 transformed cell lines and uses therefor
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2959689A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
EP3223854A1 (en) 2014-11-25 2017-10-04 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (ko) 2014-12-03 2017-07-25 제넨테크, 인크. 4급 아민 화합물 및 그의 항체-약물 접합체
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3416641A1 (en) 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
EP3416640A1 (en) 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
EP3433621A1 (en) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
KR20200032243A (ko) 2017-02-08 2020-03-25 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
CN111065638B (zh) 2017-08-18 2021-04-09 麦迪穆有限责任公司 吡咯并苯并二氮杂䓬缀合物
CN111788208B (zh) 2017-09-20 2023-11-24 Ph制药有限公司 泰兰他汀类似物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
IL296050B2 (en) 2018-08-01 2024-12-01 Immunitybio Inc A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
IL286326B2 (en) 2019-03-15 2025-10-01 Medimmune Ltd Azatidobenzodiazepine dimers and conjugates containing them for use in the treatment of cancer
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CA3236930A1 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114848822A (zh) * 2022-06-01 2022-08-05 合肥工业大学 Gpr31抑制剂在制备预防和治疗血管钙化药物中的应用
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
TW202432187A (zh) 2022-12-23 2024-08-16 美商建南德克公司 小腦蛋白降解劑結合物及其用途
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2025207642A1 (en) * 2024-03-25 2025-10-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Cxcr3 isoforms to improve recombinant receptor trafficking

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133064T2 (de) 1990-02-26 2003-03-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Identifizierung und expression von insekten-steroidrezeptor-dns-sequenzen
DE69232876D1 (de) 1991-10-01 2003-01-30 Us Gov Health & Human Serv Ein verfahren zur identifikation von liganden und ligandantagonisten
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
AU677968B2 (en) 1992-09-25 1997-05-15 H. Lundbeck A/S DNA encoding human alpha 1 adrenergic receptors and uses thereof
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
AU1173995A (en) 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
WO1995018380A1 (en) * 1993-12-30 1995-07-06 The Salk Institute For Biological Studies Novel uses for gal4-receptor constructs
US5573944A (en) 1994-07-22 1996-11-12 President And Fellows Of Harvard College Yeast cell expressing heterologous receptor kinase
EP0804575A1 (en) 1994-08-11 1997-11-05 Takeda Chemical Industries, Ltd. G protein coupled receptor protein, production, and use thereof
CA2135253A1 (en) 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
AU714642B2 (en) * 1995-06-06 2000-01-06 Human Genome Sciences, Inc. G-protein receptor HTNAD29
WO1997011159A1 (en) 1995-09-20 1997-03-27 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
FR2742033B1 (fr) * 1995-12-08 1998-01-16 Achart Jacques Appareil pour l'ouverture de coquillages de mollusques bivalves
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
EP0869975B1 (en) 1995-12-11 2007-08-15 New England Medical Center Hospitals, Inc. Assay for and uses of peptide hormone receptor ligands
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
AU3648297A (en) 1996-07-02 1998-01-21 President And Fellows Of Harvard College Receptor tyrosine phosphatase, and uses related thereto
ATE284972T1 (de) * 1996-09-24 2005-01-15 Cadus Pharmaceutical Corp Verfahren und zusammensetzungen für die identifizierung von receptor effectoren
WO1998029440A1 (en) 1996-12-27 1998-07-09 Merck & Co., Inc. Mouse galanin receptor galr2 and nucleotides encoding same
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
WO1998038217A1 (en) 1997-02-27 1998-09-03 Milt Teitler Constitutively activated serotonin receptors
NZ336479A (en) 1997-04-14 2001-10-26 Arena Pharm Inc A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
EP0878542A3 (en) 1997-04-22 2000-04-19 Smithkline Beecham Corporation cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor
JP2002508660A (ja) 1997-06-12 2002-03-19 スミスクライン ビーチャム コーポレーション Ｈｍ７４ａ受容体
US5955308A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
WO1999024569A1 (fr) 1997-11-11 1999-05-20 Ono Pharmaceutical Co., Ltd. Recepteur d'acide lysophosphatidique humain et utilisation dudit recepteur
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
ATE440865T1 (de) 1998-03-26 2009-09-15 Univ Leland Stanford Junior Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
JP2003514763A (ja) 1998-04-14 2003-04-22 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内在性の構成的に活性化されるヒトセロトニンレセプターおよびその小分子調節物質
CN1231762C (zh) * 1998-07-31 2005-12-14 阿瑞那制药公司 对候选化合物进行直接鉴定的方法
EP1111049A4 (en) 1998-09-03 2002-10-29 Asahi Chemical Ind New receptor protein and method for diagnosing inflammatory diseases using it
US20030229216A1 (en) * 1998-10-13 2003-12-11 Ruoping Chen Constitutively activated human G protein coupled receptors
KR20010080882A (ko) 1998-10-13 2001-08-25 리처드 피. 버군 쥬니어 구성적으로 활성화된 비내생성 인간 ｇ 단백질 결합형수용체
EP1153932A1 (en) 1999-02-19 2001-11-14 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
EP1200474A1 (en) 1999-07-15 2002-05-02 Solvay Pharmaceuticals B.V. Human g-protein coupled receptor
WO2001007606A1 (en) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2003510027A (ja) 1999-08-17 2003-03-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｐｇｐｃｒ−３ポリペプチドおよびそのｄｎａ配列
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
WO2001016159A1 (en) 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, theant
GB9923889D0 (en) 1999-10-08 1999-12-08 Pfizer Ltd Novel polypeptide
GB9924951D0 (en) 1999-10-21 1999-12-22 Pfizer Ltd Novel polypeptide
EP1230361A2 (en) 1999-10-27 2002-08-14 PHARMACIA & UPJOHN COMPANY G protein-coupled receptors expressed in human brain
IL149569A0 (en) 1999-11-17 2002-11-10 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors

Also Published As

Publication number Publication date
KR20010085911A (ko) 2001-09-07
HK1038040A1 (en) 2002-03-01
CA2342314A1 (en) 2000-04-20
ATE318311T1 (de) 2006-03-15
CN1398298A (zh) 2003-02-19
JP4685241B2 (ja) 2011-05-18
AU769987B2 (en) 2004-02-12
JP2003531565A (ja) 2003-10-28
WO2000022129A1 (en) 2000-04-20
NZ510331A (en) 2004-07-30
CN1329511C (zh) 2007-08-01
WO2000021987A9 (en) 2000-08-24
AU6430799A (en) 2000-05-01
DK1121431T5 (da) 2008-03-03
DK1121431T3 (da) 2006-06-26
WO2000021987A2 (en) 2000-04-20
US7410777B2 (en) 2008-08-12
KR100598752B1 (ko) 2006-07-11
ES2163384T1 (es) 2002-02-01
JP2002527727A (ja) 2002-08-27
AU2011200511A1 (en) 2011-03-03
EP1121431A1 (en) 2001-08-08
US20030105292A1 (en) 2003-06-05
EP1121431B9 (en) 2007-10-24
DE69929993T4 (de) 2008-08-28
DE69929993T2 (de) 2006-10-26
US6555339B1 (en) 2003-04-29
AU2011200016A1 (en) 2011-01-27
IL141965A (en) 2008-08-07
ES2163384T3 (es) 2006-12-01
AU2004203102B2 (en) 2007-10-18
WO2000022129A9 (en) 2000-09-14
DE1121431T1 (de) 2002-05-23
WO2000021987A3 (en) 2000-07-13
AU2004203102A1 (en) 2004-07-29
AU2008200231A1 (en) 2008-02-07
EP1121431B1 (en) 2006-02-22
IL141965A0 (en) 2002-03-10
DE69929993D1 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
JP4672866B2 (ja) 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体
US6806054B2 (en) Non-endogenous, constitutively activated known G protein-coupled receptors
KR20010080882A (ko) 구성적으로 활성화된 비내생성 인간 ｇ 단백질 결합형수용체
EP1242448A2 (en) Endogenous and non-endogenous versions of human g protein-coupled receptors
US20130165633A1 (en) Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors
US8440391B2 (en) Constitutively activated human G protein coupled receptors
JP4768946B2 (ja) ヒトｇタンパク質共役型受容体の内因性および非内因性型
AU6299199A (en) Non-endogenous, constitutively activated human g protein-coupled receptors
US20070072248A1 (en) Constitutively activated human G protein coupled receptors
EP1676861A2 (en) Non-endogenous, constitutively activated human G protein-coupled receptors
US20150153327A1 (en) Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors
HK1038040B (en) Non-endogenous, constitutively activated human g protein-coupled receptors
JP2003525018A6 (ja) 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体
HK1091214A (en) Non-endogenous, constitutively activated human g protein-coupled receptors
JP2003525018A (ja) 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体
JP2011097950A (ja) ヒトｇタンパク質共役型受容体の内因性および非内因性型
JP2011172577A (ja) 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体
EP1137776A2 (en) Non-endogenous, constitutively activated human g protein-coupled receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090925

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101224

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110120

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140128

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees